HOLLY KIMBRELL: Open Payments
NPI 1093796328 · BROOKHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 43 payments from 19 companies in 2025. Trend: 2023 $917 · 2024 $1,107 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $108 |
| AstraZeneca Pharmaceuticals LP | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. | 3 | $79 |
| Vifor Pharma, Inc. | 4 | $78 |
| Ardelyx, Inc. | 3 | $74 |
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| SCPHARMACEUTICALS INC. | 2 | $48 |
| Calliditas Therapeutics US Inc. | 2 | $45 |
| Travere Therapeutics, Inc. | 2 | $42 |
Products named: Kerendia, FARXIGA, JYNARQUE, Veltassa, IBSRELA, ACTHAR, FUROSCIX, JARDIANCE.
Industry payments across MS — which companies pay providers there.
